Comparison of Efficacy and Safety of Cilostazol/Extract of Ginkgo biloba vs. Aspirin in Carotid Atherosclerosis in Patients with Diabetes Mellitus

Article information

Diabetes Metab J. 2025;.dmj.2025.0146

Publication date (electronic) : 2025 August 13

doi : https://doi.org/10.4093/dmj.2025.0146

You-Cheol Hwang ¹

, Mi Kyung Kim ², Jung Hwan Park ³, Han Mi Yun ⁴, Sang Yong Kim^,⁵

, Soo Lim^,⁶

¹Division of Endocrinology and Metabolism, Department of Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea

²Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea

³Division of Endocrinology and Metabolism, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

⁴Physiologic Diagnostic Laboratory, Vascular Laboratory, Seoul National University Bundang Hospital, Seongnam, Korea

⁵Department of Internal Medicine, Chosun University Hospital, Chosun University College of Medicine, Gwangju, Korea

⁶Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Corresponding authors: Sang Yong Kim https://orcid.org/0000-0002-3902-622X Division of Endocrinology, Department of Internal Medicine, Chosun University College of Medicine, 309 Pilmun-daero, Dong-gu, Gwangju 61452, Korea E-mail: diabetes@chosun.ac.kr

Soo Lim https://orcid.org/0000-0002-4137-1671 Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea E-mail: limsoo@snu.ac.kr

Received 2025 February 24; Accepted 2025 May 16.

Abstract

Background

We conducted a prospective, randomized study to evaluate the combination of cilostazol (CTZ) and extract of Ginkgo biloba (EGb) and compare it with aspirin for the prevention of atherosclerosis progression in patients with type 2 diabetes mellitus (T2DM).

Methods

One hundred five patients with T2DM and increased carotid intima-media thickness (IMT) were randomly assigned to receive either CTZ 200 mg plus EGb 160 mg once daily or aspirin (ASA) 100 mg/day for 12 months. The primary endpoint was the change in maximum carotid IMT.

Results

The mean age and body mass index were 61.6±8.4 years and 25.2±3.1 kg/m² in the CTZ/EGb group and 61.6±7.6 years and 24.5±3.3 kg/m² in the ASA group, respectively. CTZ/EGb treatment reduced the maximum IMT in the bulb area (from 1.435±0.690 to 1.346±0.688 mm on the right; from 1.359±0.528 to 1.299±0.528 mm on the left), whereas ASA treatment did not, resulting in significant between-group differences (P<0.05). No significant differences were observed in the common carotid and internal carotid arteries. The CTZ/EGb group showed a reduction in triglycerides and an increase in high-density lipoprotein cholesterol levels. Additionally, aspartate and alanine aminotransferase levels decreased only in the CTZ/EGb group. There were no significant differences in Mini-Mental State Examination (MMSE) score changes or adverse events (ClinicalTrials.gov number: NCT05906199).

Conclusion

Twelve months of CTZ/EGb combination therapy significantly attenuated the progression of carotid atherosclerosis compared with aspirin in patients with T2DM.

Keywords: Aspirin; Atherosclerosis; Carotid artery diseases; Cilostazol; Diabetes mellitus, type 2

GRAPHICAL ABSTRACT

Highlights

• In T2DM patients, CTZ/EGb therapy significantly reduces carotid IMT compared to aspirin.

• CTZ/EGb improves lipid profiles and liver enzymes without cognitive or safety concerns.

• These findings support CTZ/EGb as a potential strategy to slow atherosclerosis in T2DM.

INTRODUCTION

Diabetes is a well-established risk factor for cardiovascular disease (CVD), including coronary artery disease and stroke. The risk of stroke is 2- to 3-fold higher in patients with type 2 diabetes mellitus (T2DM) compared to the general population [1]. In patients with T2DM, the prevalence of ischemic stroke is higher than that of hemorrhagic stroke compared to those without diabetes [2]. Therefore, preventing the progression of atherosclerosis to reduce CVD risk is crucial for patients with T2DM.

Many international guidelines from the USA, Europe, and Asian countries recommend antiplatelet therapy as part of the management strategy for patients with T2DM at high cardiovascular (CV) risk [3]. To identify individuals at high CV risk, several diagnostic tools have been introduced, including carotid intima-media thickness (IMT) measurement, pulse wave velocity, ankle-brachial index (ABI), and flow-mediated vasodilation [4]. Among these, carotid IMT is widely used as a surrogate marker for assessing atherosclerosis progression or regression in clinical trials due to its noninvasive nature and simplicity [5,6]. Indeed, a previous meta-analysis demonstrated that carotid IMT is a predictor of future vascular events, including stroke [7].

Importantly, recent large, randomized studies have demonstrated that aspirin does not provide significant benefits for the primary prevention of CVD; moreover, it may increase the risk of major bleeding [8-10] and even mortality [11]. Cilostazol (CTZ), a phosphodiesterase (PDE) III inhibitor, increases cyclic adenosine monophosphate concentrations, leading to the inhibition of platelet aggregation and thrombus formation [12]. Previous experimental studies have shown that CTZ treatment reduces inflammation and vascular smooth muscle cell proliferation while improving endothelial function, as well as triglyceride and high-density lipoprotein (HDL) cholesterol metabolism [13-17]. In clinical trials, CTZ treatment has also been shown to slow the progression of carotid atherosclerosis [18,19].

Extract of Ginkgo biloba (EGb) is known to enhance blood circulation by decreasing platelet activation and reducing platelet-activating factor levels [20,21]. EGb consists of two major components: flavonoids and terpenes. The flavonoid fraction exerts antioxidant effects by directly attenuating reactive oxygen species and promoting the expression of antioxidant proteins. This, in turn, increases antioxidant metabolites such as glutathione and facilitates the chelation of pro-oxidant transition metal ions [22,23]. Additionally, EGb treatment has been shown to inhibit amyloid-beta aggregation [24] and exhibit antiapoptotic properties [25].

Elderly individuals with T2DM are at a higher risk of developing vascular dementia compared to their non-diabetic counterparts [26]. This increased risk is primarily attributed to heightened oxidative stress, inflammation, and dysregulated insulin signaling, all of which contribute to neuronal damage [27,28]. The progressive nature of cognitive impairment in patients with T2DM poses significant challenges, affecting their quality of life, daily functioning, and ability to self-manage the disease [29].

Therefore, we conducted a prospective, randomized study to evaluate the efficacy of combined CTZ and EGb treatment and compare it with aspirin in preventing the progression of carotid atherosclerosis and cognitive decline in patients with T2DM.

METHODS

Study population and design

This was a prospective, randomized, active-controlled, parallel-group, open-label, multicenter, phase IV study conducted from July 2021 to June 2023 at five university hospitals in South Korea. Participants eligible for the study were patients with T2DM and peripheral artery disease, aged 20 to 75 years at the time of enrollment, who had an increased carotid IMT greater than 0.9 mm on carotid ultrasound.

The major exclusion criteria included patients with a recent history of CVD, uncontrolled hypertension, poorly controlled diabetes, acute bleeding, recently diagnosed gastric ulcers, severe kidney or liver dysfunction, or those receiving other antiplatelet therapy. Patients who had undergone or required vascular surgery, endovascular intervention, or carotid endarterectomy for peripheral artery occlusion within 1 month prior to screening. Other detailed exclusion criteria are presented in Supplementary Table 1.

Participants were randomly assigned in a 1:1 ratio to one of two treatment groups. One group received controlled-release CTZ (200 mg) and EGb (160 mg) once daily (CTZ/EGb group), while the other group received aspirin (100 mg) once daily (ASA group) for 12 months. To assess compliance, research coordinators checked the remaining pill count at each visit. The randomization order was generated using a computer-generated random number sequence. Safety assessments were performed at each visit and included physical examinations, vital signs, 12-lead electrocardiogram, laboratory tests, and monitoring for adverse events, based on both patient-reported symptoms and investigator observations. In addition, an unscheduled visit was included to allow for safety evaluations in cases of early discontinuation. All participants provided written informed consent. The study protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital (B-1604-344-002). This study was conducted in accordance with the Declaration of Helsinki and was registered at ClinicalTrials.gov (NCT05906199).

Measurement of anthropometric and biochemical parameters

Height (cm) and body weight (kg) were measured using standard procedures to the nearest 0.1 cm and 0.1 kg, respectively. Body mass index was calculated by dividing body weight by the square of height (kg/m²). Blood pressure was measured using an automated device. Before the measurement, each participant rested for at least 5 minutes while sitting in a chair with both feet flat on the floor and both arms supported at heart level.

After a 12-hour overnight fast, venous blood samples were collected in the morning. Fasting plasma glucose (FPG), total cholesterol, triglycerides, HDL-cholesterol, low-density lipoprotein cholesterol, and creatinine levels were measured using a standard automated chemistry analyzer (Hitachi 747, Hitachi, Tokyo, Japan). Glycosylated hemoglobin (HbA1c) levels were measured using a high-performance liquid chromatography-based Bio-Rad Variant II Turbo analyzer (Bio-Rad Laboratories, Hercules, CA, USA). Serum alkaline phosphatase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were measured using an autoanalyzer (TBA-200FR, Toshiba, Tokyo, Japan). Serum high-sensitivity C-reactive protein levels were measured using a high-sensitivity automated immunoturbidimetric method (CRP-Latex (II)X2, Denka Seiken Co., Tokyo, Japan).

Ultrasound imaging

An experienced sonographer at each hospital performed and analyzed the ultrasound images. To reduce bias, the radiologist was blinded to both the treatment group and the imaging time point (baseline or follow-up). The interobserver reproducibility of IMT was excellent, with an intraclass correlation coefficient (ICC) of 0.969, while the reproducibility of plaque volume was good, with an ICC of 0.805.

Carotid IMT measurement was performed offline using six clips obtained from the bulb area, the common carotid artery (CCA), and the internal carotid artery (ICA), recorded in longitudinal mode, ensuring that the carotid artery was parallel to the transducer surface (horizontal in the image). The focal zone was set to the far walls of each site, and the intima-lumen and media-adventitia interfaces were traced, followed by processing using a previously described algorithm [30].

Carotid plaque was defined as a local thickening of the carotid IMT greater than 50% compared to the surrounding vessel wall, an IMT greater than 1.5 mm, or a local thickening greater than 0.5 mm [31]. If plaque was identified during the review of gray-scale serial images from three-dimensional (3D) sweep recordings, the beginning and end frames of the plaque were specified. The quantification laboratory-vascular plaque quantification (QLAB-VPQ) plug-in was used to outline the vessel walls and residual lumen in contiguous frames where plaque was present. For plaque volume measurement, each image was analyzed using an automated value provided by QLAB-VPQ, which was manually adjusted if the plaque contour was unclear. The plaque areas from all images in the entire sequence of each carotid artery (right/left) were summed to calculate the plaque burden [32].

Mini-Mental Status Examination

Although clinically distinct from dementia, the diagnosis of mild cognitive impairment (MCI) remains challenging due to the lack of clear diagnostic criteria and its primary reliance on clinical judgment. MCI is characterized by impaired cognition with minimal impact on instrumental activities of daily living [33]. Mini-Mental State Examination (MMSE) scores between 25 and 28 indicate a suboptimal cognitive status, suggestive of MCI [33,34]. The MMSE score was assessed using the validated Korean version (K-MMSE 2) (Hakjisa Publisher & Inpsyt Inc., Seoul, Korea).

End points

The primary endpoint was the change in maximum carotid IMT at the bulb, measured by 3D carotid ultrasound after 12 months of treatment. The secondary endpoints included changes in the maximum IMT of the right and left CCA and ICA from baseline. Other secondary endpoints involved changes in risk factors for atherosclerosis, such as lipid parameters, as well as changes in liver and kidney function.

Statistical analysis

Continuous data are presented as the mean±standard deviation, while categorical data are presented as numbers (%). The baseline characteristics were compared using Student’s t-test for continuous variables and the chi-squared test for categorical parameters. The Student’s t-test was applied after confirming normality using Kolmogorov-Smirnov Z test. A paired t-test was used to evaluate changes between baseline and post-treatment time points. All statistical analyses were conducted using SPSS for Windows version. 22.0 (IBM, Armonk, NY, USA). Statistical significance was set at P<0.05.

For the power calculation, since no studies have evaluated the effect of CTZ on carotid artery plaque volume, we referred to a previous study that assessed the efficacy of CTZ in preventing the progression of intracranial arterial stenosis. In that study, after 6 months of treatment with either CTZ or aspirin, 6.7% of patients in the CTZ group and 28.8% in the aspirin group showed progression of intracranial stenosis [35]. Based on these results, we conservatively assumed a 10% progression of carotid artery stenosis in the CTZ group and a 30% progression in the aspirin group after 12 months of treatment for carotid atherosclerosis. With an α-level of 0.05, a β-level of 0.20 for a superiority design, and a 15% drop-out rate, the minimum required sample size was 100 patients in total (50 per group, with 1:1 randomization).

RESULTS

Subject allocation and baseline characteristics

A total of 120 patients were screened, and 105 were randomized: 52 patients in the CTZ/EGb group and 53 in the ASA group. The mean duration of T2DM was over 10 years in both groups. After excluding those with poor adherence, early withdrawal, or protocol violations, 37 patients in the CTZ/EGb group and 39 in the ASA group were included in the per-protocol set, which was used for the primary analysis of changes in carotid IMT. Reasons for exclusion and participant disposition are shown in Supplementary Fig. 1.

The demographic and clinical characteristics of the participants enrolled in the study are presented in Table 1. The two groups were well-matched with respect to these characteristics. More than 40% of patients were being treated for hypertension, and over 80% were being treated for dyslipidemia.

Table 1.

Baseline characteristics of the study populations (intention-to-treat group)

Changes in carotid atherosclerosis after the 12-month treatment

Table 2, Fig. 1 summarize the changes in carotid atherosclerosis observed after treatment, as assessed by carotid ultrasound. The CTZ/EGb treatment resulted in a decrease in the maximum IMT at both the right and left bulb areas (from 1.435±0.690 to 1.346±0.688 mm at the right bulb; from 1.359±0.528 to 1.299±0.528 mm at the left bulb, with P=0.044 and P=0.041, respectively). In contrast, the maximum IMT at the bulb areas in the ASA group did not show significant changes during treatment. As a result, the delta change in IMT was significantly different between the two groups (Table 2, Fig. 1). However, no significant differences were observed in the CCA and ICA areas between the two groups

Table 2.

Changes in carotid intima-media thickness after 12-month cilostazol/EGb or aspirin treatment (per-protocol analysis)

Fig. 1.

Changes in maximum intima-media thickness (IMT) at the right and left bulb areas (A, B), right and left common carotid arteries (CCA) (C, D), and right and left internal carotid arteries (ICA) (E, F) after the 12-month treatment with cilostazol/extract of Ginkgo biloba (EGb) and aspirin. ^aP<0.05, which was calculated using a paired t-test between the values recorded at the baseline and after treatment.

Changes in anthropometric and laboratory parameters after the 12-month treatment

Table 3 shows the changes in various parameters after treatment. There were no significant changes in systolic or diastolic blood pressure in either group after the 12-month treatment period. Heart rate also showed no significant change in either group.

Table 3.

Changes in anthropometric parameters and biomarkers after 12-month treatment (per-protocol analysis)

FPG levels did not change significantly in either group. Among the lipid parameters, there was a significant decrease in triglyceride levels by 17.9 mg/dL and a significant increase in HDL-cholesterol levels by 5.6 mg/dL only in the CTZ/EGb group. In contrast, triglyceride levels increased insignificantly, and HDL-cholesterol levels did not change in the ASA group. As a result, the delta changes in triglyceride and HDL-cholesterol levels were significantly different between the two groups (Table 3).

Regarding liver enzymes, a significant reduction in AST and ALT levels was observed only in the CTZ/EGb group, resulting in significant differences in AST levels between the two groups.

Changes in the MMSE score

The changes in MMSE scores over 12 months are shown in Table 3. At 12 months, the CTZ/EGb group exhibited a slight increase in MMSE scores, from 27.00±2.57 to 27.27±2.42, whereas the MMSE score in the ASA group remained unchanged, resulting in no meaningful difference between the two groups.

Adverse events

Overall, 12 patients (27.5%) in the CTZ/EGb group reported any adverse events, compared to seven patients (13.7%) in the ASA group, as shown in Table 4. This difference was not statistically significant. Treatment-emergent adverse events were also similar between the groups: five patients (9.8%) in the CTZ/EGb group versus two patients (3.9%) in the ASA group. No serious adverse events, such as bleeding, were reported in this study. Headache was reported by five patients in the CTZ/EGb group, but none in the ASA group. Additionally, one patient in the CTZ/EGb group complained of palpitations.

Table 4.

Adverse events during the study period

DISCUSSION

In this prospective, randomized study, treatment with a combination of CTZ and EGb for 12 months significantly reduced the IMT of the carotid arteries compared to aspirin in patients with T2DM. The beneficial effects of CTZ on the vessels were accompanied by increases in HDL-cholesterol levels and decreases in triglycerides, as well as liver enzyme levels.

Carotid atherosclerosis is a well-known risk factor for ischemic cerebrovascular disease [36]. Carotid ultrasound is frequently used to assess carotid atherosclerosis due to its noninvasive nature and simplicity [37,38]. In particular, carotid IMT measured by carotid ultrasound is commonly used to assess the progression or regression of atherosclerosis, both in clinical practice and clinical trials.

The measurement of IMT in carotid arteries has become widely used for evaluating the severity of atherosclerosis because of its noninvasive nature and simplicity. Several studies have evaluated the effects of CTZ on carotid atherosclerosis or cerebrovascular disease [18,19,35,39]. In a randomized trial, treatment with CTZ for 2 years resulted in regression of the maximum carotid IMT compared to aspirin treatment [19]. In that study, the patients had T2DM and peripheral artery disease, as confirmed by the ABI test (<1.0). Another study of patients with T2DM without evident CVD found that CTZ treatment led to a greater reduction in carotid IMT compared to aspirin over a 3-year treatment period [40]. More recently, our study also demonstrated a decrease in maximum carotid IMT following CTZ treatment [41].

CTZ is known to have beneficial effects on endothelial function by modulating the expression of PDE III in endothelial cells. It also enhances vascular sensitivity to endogenous vasodilators, such as prostaglandins, and inhibits both primary and secondary platelet aggregation induced by collagen, adenosine diphosphate, arachidonic acid, and epinephrine [42].

In this study, a significant increase in serum HDL-cholesterol and a significant decrease in triglyceride levels were observed only in the CTZ/EGb group, which is in accordance with the findings of previous studies [18,19,43]. CTZ therapy increases lipoprotein lipase activity, which plays a crucial role in lipid metabolism in adipose tissue [17]. Furthermore, the decrease in hepatic triglyceride secretion by potentiating the effect of glucagon to inhibit very-low-density lipoprotein secretion may also contribute to the beneficial effects of CTZ on lipid metabolism [17]. In a previous study, CTZ treatment induced changes in lipid components in carotid plaque, as assessed by magnetic resonance imaging [39]. These results suggest that CTZ has a favorable effect on atheromatous plaque composition by altering lipid metabolism and reducing fat content. Another finding in this study was a decrease in AST and ALT levels in the CTZ/EGb group. Elevated liver enzyme activity is linked to fatty infiltration in the liver, which is associated with CVD [44]. This result may further support CTZ’s role in improving vascular health.

We previously published a clinical study in which treatment with CTZ for 1 year decreased the plaque volume in the coronary arteries in patients with T2DM [43]. We also found that CTZ treatment may improve endothelial function in the arteries of the lower extremities, assessed by a specific laser Doppler, a novel technology that can evaluate vascular circulation in the early phase [45,46]. Another recent study suggested CTZ’s potential as an effective treatment for diabetic endothelial dysfunction and vascular disease by reducing inflammasome activity [47]. These data support the idea that improvement in vascular function can be expected following CTZ treatment.

Previously, it was reported that treatment with EGb decreased homocysteine-induced intimal thickening following balloon injury in the rabbit abdominal aorta [48]. They found that EGb treatment was associated with the suppression of matrix metalloproteinase-9 (MMP-9) expression and an increase in endogenous p21 expression. We also reported that EGb761 treatment mitigated the development of carotid atherosclerosis in obese diabetic rats [49]. EGb761 significantly suppressed the proliferation and migration of vascular smooth muscle cells, promoted apoptosis, and reduced inflammatory processes [49].

In this study, no significant change was observed in the MMSE scores over 12 months in the CTZ/EGb combination treatment group. Considering the high baseline MMSE scores (around 27) in both groups, meaningful changes were unlikely with in either the CTZ/EGb or ASA treatment groups.

Regarding adverse events, overall and treatment-emergent adverse events did not differ between the two groups. Among adverse events of specific interest, major bleeding was not reported in either group. Headache was reported in five patients in the CTZ/EGb group but none in the ASA group. Additionally, one patient in the CTZ/EGb group reported palpitation, while one case of angina pectoris was reported in the ASA group.

Our study had several strengths. First, we evaluated carotid atherosclerosis at three different sites. Second, the study employed a prospective, randomized design over 12 months. Third, we assessed various markers associated with atherosclerosis, including liver enzymes, glucose, lipid profiles, and inflammatory markers. However, several limitations should be noted. First, we did not measure hard endpoints, such as CV or cerebrovascular events. Second, the baseline MMSE scores were relatively high, which may explain why no significant improvement was observed in the MMSE score. Third, although we did not specifically monitor individual medications such as sodium-glucose cotransporter 2 (SGLT2) inhibitors or statins throughout the study period, we did monitor the overall use of glucose-lowering and lipid-lowering agents. Participants were required to have been on stable doses for at least 30 days before enrollment, and dose adjustments were restricted during the study. Given that baseline use of these medications was comparable between groups and major dose changes were avoided, their impact on study outcomes is likely to have been minimal. Fourth, we did not collect data on body weight changes during the follow-up period. Although the study medications are not known to affect body weight, body weight can influence lipid markers, such as triglycerides and HDL-cholesterol. Therefore, caution is needed when interpreting the lipid outcomes. Fifth, while the decrease in liver enzymes may suggest improved hepatic function, it is uncertain whether this reflects changes in hepatic steatosis due to the absence of imaging or other assessments. Finally, a major limitation of this study was the absence of data on smoking status, a well-established risk factor for atherosclerosis.

In conclusion, the combined treatment of CTZ and EGb for 12 months significantly reduced carotid IMT in patients with T2DM compared to treatment with aspirin. These results suggest that the combination of CTZ and EGb may be an effective treatment option for the primary prevention of CVD in patients with T2DM. Longer-term, large-scale studies are needed to confirm these findings.

SUPPLEMENTARY MATERIALS

Supplementary materials related to this article can be found online at https://doi.org/10.4093/dmj.2025.0146

Supplementary Table 1.

Exclusion criteria

dmj-2025-0146-Supplementary-Table-1.pdf

Supplementary Fig. 1.

Disposition of patients and reasons for follow-up loss. CTZ, cilostazol; EGb, extract of Ginkgo biloba; ASA, aspirin. ^aThe reasons for exclusion from the PPS were overlapped.

dmj-2025-0146-Supplementary-Fig-1.pdf

Notes

CONFLICTS OF INTEREST

Sang Yong Kim has been associate editors of the Diabetes & Metabolism Journal since 2022. They were not involved in the review process of this article. Otherwise, there was no conflict of interest.

AUTHOR CONTRIBUTIONS

Conception or design: S.L.

Acquisition, analysis, or interpretation of data: Y.C.H., M.K.K., J.H.P., H.M.Y., S.Y.K., S.L.

Drafting the work or revising: Y.C.H., S.Y.K., S.L.

Final approval of the manuscript: all authors.

FUNDING

This research was funded by SK Chem. (Seoul, Korea) through a subcontract with Seoul National University Bundang Hospital (Seongnam, Korea). The funding agency had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

ACKNOWLEDGMENTS

None

References

1. Chen R, Ovbiagele B, Feng W. Diabetes and stroke: epidemiology, pathophysiology, pharmaceuticals and outcomes. Am J Med Sci 2016;351:380–6.

2. Tun NN, Arunagirinathan G, Munshi SK, Pappachan JM. Diabetes mellitus and stroke: a clinical update. World J Diabetes 2017;8:235–48.

3. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care 2019;42(Suppl 1):S103–23.

4. Kobayashi K, Akishita M, Yu W, Hashimoto M, Ohni M, Toba K. Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis 2004;173:13–8.

5. Kawamori R, Yamasaki Y, Matsushima H, Nishizawa H, Nao K, Hougaku H, et al. Prevalence of carotid atherosclerosis in diabetic patients: ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 1992;15:1290–4.

6. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577–81.

7. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007;115:459–67.

8. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.

9. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134–41.

10. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265–71.

11. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018;379:1519–28.

12. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003;9:2289–302.

13. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985;35(7A):1144–9.

14. Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, et al. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. J Pharmacol Exp Ther 2009;329:571–9.

15. Ota H, Eto M, Kano MR, Ogawa S, Iijima K, Akishita M, et al. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol 2008;28:1634–9.

16. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988;36:313–20.

17. Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, Kimura Y. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 2000;152:299–305.

18. Huh JH, Seok H, Lee BW, Kang ES, Lee HC, Cha BS. Effect of cilostazol on carotid intima-media thickness in type 2 diabetic patients without cardiovascular event. Endocrine 2014;47:138–45.

19. Katakami N, Kim YS, Kawamori R, Yamasaki Y. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 2010;121:2584–91.

20. Smith PF, Maclennan K, Darlington CL. The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacol 1996;50:131–9.

21. Oyama Y, Chikahisa L, Ueha T, Kanemaru K, Noda K. Ginkgo biloba extract protects brain neurons against oxidative stress induced by hydrogen peroxide. Brain Res 1996;712:349–52.

22. Smith JV, Luo Y. Elevation of oxidative free radicals in Alzheimer’s disease models can be attenuated by Ginkgo biloba extract EGb 761. J Alzheimers Dis 2003;5:287–300.

23. Singh SK, Srivastav S, Castellani RJ, Plascencia-Villa G, Perry G. Neuroprotective and antioxidant effect of Ginkgo biloba extract against AD and other neurological disorders. Neurotherapeutics 2019;16:666–74.

24. Shi C, Liu J, Wu F, Yew DT. Ginkgo biloba extract in Alzheimer’s disease: from action mechanisms to medical practice. Int J Mol Sci 2010;11:107–23.

25. Smith JV, Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 2004;64:465–72.

26. Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L. Uncontrolled diabetes increases the risk of Alzheimer’s disease: a population-based cohort study. Diabetologia 2009;52:1031–9.

27. Singh DD, Shati AA, Alfaifi MY, Elbehairi SE, Han I, Choi EH, et al. Development of dementia in type 2 diabetes patients: mechanisms of insulin resistance and antidiabetic drug development. Cells 2022;11:3767.

28. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol 2018;14:591–604.

29. Srikanth V, Sinclair AJ, Hill-Briggs F, Moran C, Biessels GJ. Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol 2020;8:535–45.

30. Polak JF, Pencina MJ, Herrington D, O’Leary DH. Associations of edge-detected and manual-traced common carotid intima-media thickness measurements with Framingham risk factors: the multi-ethnic study of atherosclerosis. Stroke 2011;42:1912–6.

31. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004-2006): an update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007;23:75–80.

32. Sillesen H, Muntendam P, Adourian A, Entrekin R, Garcia M, Falk E, et al. Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study. JACC Cardiovasc Imaging 2012;5:681–9.

33. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. JAMA 2014;312:2551–61.

34. Tsoi KK, Chan JY, Hirai HW, Wong SY, Kwok TC. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med 2015;175:1450–8.

35. Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005;36:782–6.

36. Mathiesen EB, Johnsen SH. Ultrasonographic measurements of subclinical carotid atherosclerosis in prediction of ischemic stroke. Acta Neurol Scand Suppl 2009;189:68–72.

37. Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA, D’Agostino RB Sr. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011;365:213–21.

38. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004;109:1089–94.

39. Yamaguchi Oura M, Sasaki M, Ohba H, Narumi S, Oura K, Uwano I, et al. Carotid plaque characteristics on magnetic resonance plaque imaging following long-term cilostazol therapy. J Stroke Cerebrovasc Dis 2014;23:2425–30.

40. Hong S, Nam M, Little BB, Paik S, Lee K, Woo J, et al. Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness. Heart Vessels 2019;34:1758–68.

41. Lee DH, Chun EJ, Moon JH, Yun HM, Lim S. Effect of cilostazol on carotid plaque volume measured by three-dimensional ultrasonography in patients with type 2 diabetes: the FANCY study. Diabetes Obes Metab 2020;22:2257–66.

42. Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013;127:2307–15.

43. Lee DH, Chun EJ, Oh TJ, Kim KM, Moon JH, Choi SH, et al. Effect of cilostazol, a phosphodiesterase-3 inhibitor, on coronary artery stenosis and plaque characteristics in patients with type 2 diabetes: ESCAPE study. Diabetes Obes Metab 2019;21:1409–18.

44. Lim S, Taskinen MR, Boren J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obes Rev 2019;20:599–611.

45. Fabregate-Fuente M, Arbeitman CR, Cymberknop LJ, Bara-Ledesma N, Arriazu-Galindo M, Martin-Fernandez L, et al. Characterization of microvascular post occlusive hyperemia using laser doppler flowmetry technique in subjects with cardiometabolic disorders. Annu Int Conf IEEE Eng Med Biol Soc 2019;2019:514–7.

46. Lanting SM, Barwick AL, Twigg SM, Johnson NA, Baker MK, Chiu SK, et al. Post-occlusive reactive hyperaemia of skin microvasculature and foot complications in type 2 diabetes. J Diabetes Complications 2017;31:1305–10.

47. Wang X, Huang H, Su C, Zhong Q, Wu G. Cilostazol ameliorates high free fatty acid (FFA)-induced activation of NLRP3 inflammasome in human vascular endothelial cells. Artif Cells Nanomed Biotechnol 2019;47:3704–10.

48. Liu F, Zhang J, Yu S, Wang R, Wang B, Lai L, et al. Inhibitory effect of Ginkgo biloba extract on hyperhomocysteinemia-induced intimal thickening in rabbit abdominal aorta after balloon injury. Phytother Res 2008;22:506–10.

49. Lim S, Yoon JW, Kang SM, Choi SH, Cho BJ, Kim M, et al. EGb761, a Ginkgo biloba extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetes. PLoS One 2011;6e20301.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Characteristic	Cilostazol/EGb (n=52)	Aspirin (n=53)	P value
Age, yr	61.62±8.40	61.62±7.61	0.8852
Sex, male/female	35/17	40/13	0.3545
Height, cm	165.42±8.20	165.70±7.76	0.8545
Weight, kg	69.18±10.90	67.40±11.40	0.3066
BMI, kg/m²	25.22±3.17	24.49±3.29	0.2501
Duration of DM, yr	11.06±7.38	13.72±8.44	0.1070
SBP, mm Hg	134.37±10.67	130.76±13.34	0.1346
DBP, mm Hg	76.08±9.27	75.29±10.93	0.6969
Heart rate, bpm	81.04±10.21	78.96±11.27	0.3535
Laboratory findings
FPG, mg/dL	139.52±30.31	133.76±33.21	0.3561
HbA1c, %	7.20±0.99	7.31±0.78	0.5110
Total cholesterol, mg/dL	141.96±32.43	148.23±34.18	0.7681
Triglycerides, mg/dL	137.48±83.54	109.47±45.80	0.0658
HDL-cholesterol, mg/dL	47.51±12.95	48.94±10.61	0.3973
LDL-cholesterol, mg/dL	77.74±21.73	81.32±30.25	0.8375
Creatinine, mg/dL	0.82±0.18	0.82±0.20	0.9693
ALP, IU/L	69.35±17.96	68.21±18.64	0.6170
AST, IU/L	28.01±14.83	25.92±10.58	0.9565
ALT, IU/L	29.81±20.45	28.70±17.67	0.7267
hsCRP, mg/dL	0.14±0.24	0.14±0.20	0.4417
Antidiabetic medication
Oral antidiabetic agents	51 (98.1)	49 (92.5)
Insulins	8 (15.4)	7 (13.2)
Antihypertensive medication
ACE inhibitor/ARB	14 (26.9)	10 (18.9)
ARB/CCB combination	7 (13.5)	9 (17.0)
CCB	3 (5.8)	2 (3.8)
Lipid-loweringmedication	42 (80.8)	43 (81.1)
Statin	40 (76.9)	43 (81.1)
Fibrate	4 (7.7)	1 (1.9)
Ezetimibe	7 (13.5)	7 (13.2)
Comorbidity			0.1179
Dyslipidemia	43 (82.7)	43 (81.1)
Hypertension	24 (46.2)	28 (52.8)
Peripheral vascular disorder	0	1 (1.9)
Angina pectoris	2 (3.9)	0
Cerebral infarction/ischemia	1 (1.9)	1 (1.9)

Carotid IMT	Cilostazol/EGb group (n=37)			Aspirin group (n=39)			P value^b
Carotid IMT	Baseline	After 12 months	P value^a	Baseline	After 12 months	P value^a	P value^b
At bulb, right, mm	1.435±0.690	1.346±0.688	0.010	1.478±0.659	1.547±0.702	0.324	0.044
At bulb, left, mm	1.359±0.528	1.299±0.528	0.081	1.508±0.726	1.575±0.962	0.188	0.041
At CCA, right, mm	0.888±0.297	0.863±0.303	0.260	0.997±0.410	0.988±0.444	0.915	0.861
At CCA, left, mm	1.093±0.698	1.020±0.549	0.115	0.953±0.502	0.948±0.483	0.853	0.199
At ICA, right, mm	1.248±0.575	1.197±0.595	0.412	1.259±0.529	1.257±0.478	0.979	0.609
At ICA, left, mm	1.602±1.150	1.343±0.705	0.104	1.436±0.587	1.414±0.620	0.661	0.130

Variable	Cilostazol/EGb (n=37)			Aspirin group (n=39)			P value^b
Variable	Baseline	After 12 months	P value^a	Baseline	After 12 months	P value^a	P value^b
SBP, mm Hg	133.70±9.01	132.38±13.77	0.505	130.64±12.25	132.64±12.63	0.367	0.264
DBP, mm Hg	75.30±8.45	72.92±8.17	0.150	74.69±11.29	75.15±8.56	0.761	0.202
Heart rate, bpm	80.73±10.84	83.38±11.70	0.205	79.82±12.08	79.10±11.03	0.615	0.182
WBC, 10³/μL	6.51±1.40	6.35±1.33	0.180	7.31±2.20	7.52±2.07	0.270	0.131
Hemoglobin, g/dL	13.88±1.50	13.72±1.61	0.350	14.25±1.16	14.49±1.19	0.026	0.061
Platelet, 10³/μL	223.81±54.09	236.95±57.29	0.004	227.23±45.64	238.95±55.17	0.013	0.751
FPG, mg/dL	138.90±31.37	138.57±39.16	0.854	135.78±35.63	142.54±39.98	0.060	0.083
Total cholesterol, mg/dL	142.86±36.92	153.00±30.95	0.196	147.00±30.54	151.13±31.18	0.193	0.893
Triglycerides, mg/dL	147.24±93.70	129.51±126.51	0.019	109.05±37.30	132.87±68.66	0.075	0.003
HDL-cholesterol, mg/dL	48.08±13.93	53.70±15.36	<0.001	48.94±9.93	50.46±10.89	0.170	0.015
LDL-cholesterol, mg/dL	79.02±22.60	81.76±22.62	0.243	79.65±29.38	81.85±28.08	0.367	0.917
Uric acid, mg/dL	5.17±1.56	4.92±1.44	0.049	5.12±1.12	5.03±1.20	0.400	0.297
Creatinine, mg/dL	0.82±0.18	0.85±0.23	0.041	0.82±0.17	0.82±0.16	0.806	0.066
ALP, IU/L	71.92±19.11	71.41±17.75	0.810	66.03±19.11	68.41±20.33	0.199	0.405
AST, IU/L	27.64±15.16	23.73±12.13	0.002	26.22±11.78	26.49±9.81	0.583	0.010
ALT, IU/L	28.55±19.47	23.78±14.21	0.049	29.44±18.75	28.72±13.66	0.487	0.061
hsCRP, mg/dL^c	0.13±0.28	0.07±0.05	0.371	0.14±0.15	0.18±0.44	0.851	0.666
MMSE score	27.00±2.57	27.27±2.42	0.471	27.31±2.65	27.31±2.93	0.752	0.603

Variable	Cilostazol/EGb (n=51)	Aspirin (n=51)	P value
All adverse events	14 (27.5)	7 (13.7)	0.087
Treatment-emergent adverse events	5 (9.8)	2 (3.9)	0.436
Serious adverse events	1 (2.0)	2 (3.9)	1.000
Serious treatment-emergent adverse events	0	0	-
Types
Angina pectoris	0	1 (2.0)	NS
Headache	5 (9.8)	0	0.027
COVID-19 infection	3 (5.9)	1 (2.0)	NS
Abdominal discomfort	0	1 (2.0)	NS
Diarrhoea	1 (2.0)	0	NS
Dyspepsia	1 (2.0)	0	NS
Functional gastrointestinal disorder	1 (2.0)	0	NS
Nausea	1 (2.0)	0	NS
Palpitations	1 (2.0)	0	NS
Ventricular extrasystoles	0	1 (2.0)	NS
Cellulitis	0	1 (2.0)	NS
Benign prostatic hyperplasia	1 (2.0)	0	NS
Arthralgia or arthritis	1 (2.0)	1 (2.0)	NS
Bleeding	0	0	-